Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Funding a Cure for HIV/AIDS

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
NIH plans to invest an additional $100 million over the next three fiscal years.

At a White House event today to mark the 25th annual World AIDS Day, President Obama announced that the National Institutes of Health plans to redirect AIDS research funds to expand support for research directed toward a cure for HIV. 

In the three decades since AIDS was first reported, the NIH has been the global leader in research to understand, prevent, diagnose, and treat HIV infection and its many associated conditions. NIH-funded researchers — in partnership with academia and the biotechnology and pharmaceutical industries — have helped develop more than 30 life-saving antiretroviral drugs and drug combinations for treating HIV infection. These antiretroviral drugs have transformed life with HIV infection for those who have access to and can tolerate the therapies. However, treatment requires lifelong access and adherence to these medications and management of treatment-related toxicities and clinical complications.

Important recent advances in basic and therapeutics research aimed at eliminating viral reservoirs in the body are spurring scientists to design and conduct research aimed at a cure or lifelong remission of HIV infection. Key stakeholders from academia, government, foundations, advocacy groups and industry have concluded that developing a cure for HIV is one of the most important biomedical challenges of the 21st century. This will require an extraordinary, collaborative global effort, including public-private partnerships and innovative alliances to share scientific expertise and accelerate the search for a cure.

In a presentation at the White House event today, Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, the component of NIH with the largest investment in HIV/AIDS research, discussed the public health and scientific rationale for expanded research in this area.

“Although the HIV/AIDS pandemic can theoretically be ended with a concerted and sustained scale-up of implementation of existing tools for HIV prevention and treatment, the development of a cure is critically important, as it may not be feasible for tens of millions of people living with HIV infection to access and adhere to a lifetime of antiretroviral therapy,” Dr. Fauci noted. “Our growing understanding of the cellular hiding places or ‘reservoirs’ of HIV, the development of new strategies to minimize or deplete these reservoirs, and encouraging reports of a small number of patients who have little or no evidence of virus despite having halted antiretroviral therapy, all suggest that the time is ripe to pursue HIV cure research with vigor.”

Funding for these new initiatives will come from existing resources and a redirection of funds from expiring AIDS research grants over the next three years. NIH Director Francis S. Collins, M.D., Ph.D., said, “Flat budgets and cuts from sequestration have had a profound and damaging impact on biomedical research, but we must continue to find ways to support cutting-edge science, even in this environment. AIDS research is an example of an area where hard-won progress over many years has resulted in new and exciting possibilities in basic and clinical science in AIDS that must be pursued.”

Jack Whitescarver, Ph.D., director of the Office of AIDS Research, a component of the Office of the Director of NIH, said, “We have listened very carefully to the scientific consensus of experts from within the NIH and around the world. We have been building the portfolio of HIV cure research over the past few years, and now is the time to accelerate our research focused specifically toward the goal of sustained or lifelong remission, in which patients control or even eliminate HIV without the need for lifelong antiretroviral therapy.”

It is anticipated that a significant portion of the new investment will support basic research, which will also benefit all other areas of AIDS research, as well as research on other diseases. These studies will include research on viral reservoirs, viral latency, and viral persistence, as well as studies of neutralizing antibodies. Research on animal models, drug development and preclinical testing of more potent antiretroviral compounds capable of diminishing viral reservoirs, and clinical research, including studies on therapeutic vaccines and other immune enhancers, will also be supported.

Other high-priority AIDS research will continue to be supported. These priorities include: prevention research, including vaccines, microbicides, and other biomedical and behavioral prevention strategies, such as the use of antiretroviral drugs as prevention; research to develop better, less toxic treatments and to investigate how genetic determinants, sex, gender, race, age, nutritional status, treatment during pregnancy, and other factors, including stigma and adherence, interact to affect treatment success or failure and/or disease progression; and studies to address the increased incidence of malignancies, cardiovascular, neurologic, and metabolic complications, and premature aging associated with long-term HIV disease and antiretroviral treatment. Through all of this research, NIH is committed to the ultimate goal of a world without AIDS.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Wednesday, December 07, 2016
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Wednesday, December 07, 2016
Uncovering Cerebral Malaria’s Deadly Agents
NIH scientists film inside mouse brains to uncover biology behind the disease.
Wednesday, December 07, 2016
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Wednesday, November 30, 2016
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Wednesday, November 30, 2016
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Wednesday, November 23, 2016
Food Additives Promote Inflammation, Colon Cancer
Dietary emulsifiers promoted colon cancer in a mouse model by altering gut microbes and increasing gut inflammation.
Wednesday, November 23, 2016
Protein-Folding Gene Helps Heal Wounds
Researchers identified a protein that dramatically accelerates wound healing in animal models.
Wednesday, November 23, 2016
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Monday, November 21, 2016
Big Data for Infectious Disease Surveillance
NIH-led effort examines use of big data from health records and other digital sources for uses in infectious disease surveillance.
Tuesday, November 15, 2016
Potential Therapies Against Drug-Resistant Bacteria Identified
Researchers create new identification method for drug and drug combinations that may combat resistant infections.
Thursday, November 10, 2016
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Tuesday, November 08, 2016
Genetic Markers Predict Malaria Treatment Failure
By comparing 297 parasite genomes to a reference malaria parasite genome, researchers have identified two genetic markers that are strongly associated with the parasites’ ability to resist piperaquine.
Monday, November 07, 2016
Cannabinoid Receptor Structure Revealed
Scientists provided a detailed view of the primary molecule through which cannabinoids exert their effects on the brain. The findings might help guide the design of more targeted medicines with fewer side effects.
Wednesday, November 02, 2016
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Friday, October 28, 2016
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Personality Traits, Psychiatric Disorders Linked to Specific Genomic Locations
Researchers have unearthed genetic correlations between personality traits and psychiatric disorders.
Forensic 3D Documentation of Skin Injuries
In this study, the validity of using photogrammetry for documenting injuries in a pathological context was demonstrated.
3-D Printed Dog’s Nose Improves Vapor Detection
By mimicking how dogs get their whiffs, a team of government and university researchers have demonstrated that “active sniffing” can improve by more than 10 times the performance of current technologies that rely on continuous suction to detect trace amounts of explosives and other contraband.
New Markers for Forensic Body-fluid Identification
University of Bonn researchers have successfully identified specific Micro-RNA signatures to help forensically identify body fluids.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!